{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:18:01Z","timestamp":1762507081085,"version":"3.40.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.amjcard.2017.04.041","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T09:24:05Z","timestamp":1494494645000},"page":"404-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-4920","authenticated-orcid":false,"given":"Ruchit R.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascha","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Meggo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"McElderry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vance","family":"Plumb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish","family":"Doppalapudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Pentecost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Maddox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.04.041_bib1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jce.12143","article-title":"Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation","volume":"24","author":"Maddox","year":"2013","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.04.041_bib2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.04.041_bib3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2017.04.041_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jce.12928","article-title":"Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study","volume":"27","author":"Kuwahara","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.04.041_bib5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/pace.12553","article-title":"Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation","volume":"38","author":"Nagao","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.04.041_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/jce.12856","article-title":"Apixaban, rivaroxaban, and dabigatran in patients undergoing atrial fibrillation ablation","volume":"27","author":"Rillig","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.04.041_bib7","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.hrthm.2015.02.028","article-title":"Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study","volume":"12","author":"Di Biase","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.amjcard.2017.04.041_bib8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10840-016-0141-6","article-title":"Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients","volume":"46","author":"Blandino","year":"2016","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.amjcard.2017.04.041_bib9","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/europace\/eus027","article-title":"HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design","volume":"14","author":"Calkins","year":"2012","journal-title":"Europace"},{"key":"10.1016\/j.amjcard.2017.04.041_bib10","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.04.041_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/CIRCULATIONAHA.107.727784","article-title":"Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period","volume":"116","author":"Wazni","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.04.041_bib12","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.04.041_bib13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/jce.12975","article-title":"Clinical impact of heparin kinetics during catheter ablation of atrial fibrillation: meta-analysis and meta-regression","volume":"27","author":"Briceno","year":"2016","journal-title":"J\u00a0Cardiovasc Electrophysiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917307774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917307774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T20:26:20Z","timestamp":1535833580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917307774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0002914917307774"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.04.041","relation":{},"ISSN":["0002-9149"],"issn-type":[{"type":"print","value":"0002-9149"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}